Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galenica AG (GALE.SW)
Bern, CH
Galenica AG stands as a leading healthcare services company, serving both the Swiss market and international clients. Its operations are organized into two principal divisions: "Products & Care" and "Logistics & IT." The "Products & Care" division oversees an extensive network of 520 pharmacies, comprising 368 directly owned outlets and 152 partner-affiliated pharmacies, operating under the recognized brand names of Amavita, Sun Store, and Coop Vitality. Beyond retail pharmacy services, this segment also provides medication for patients receiving home-based treatment. It is also responsible for the introduction and distribution of a diverse portfolio of consumer health, pharmaceutical, and parapharmaceutical products, in addition to offering vital marketing and sales support to its collaborators within the healthcare sector. The "Logistics & IT" division specializes in offering a suite of pre-wholesale services tailored for pharmaceutical and healthcare enterprises. These services encompass essential functions such as secure storage, efficient distribution, and comprehensive debt collection. Furthermore, this segment provides various logistics and information technology solutions, including a master data system specifically developed for the healthcare industry. It actively creates advanced management solutions relevant to the healthcare market and publishes technical information on pharmaceutical products in both printed and electronic formats, alongside delivering complete management tools for pharmacies. Founded in 1927, Galenica AG maintains its headquarters in Bern, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.91% | -0.06% | +0.12% | -13.27% | -8.56% | -15.29% | -2.17% | +17.23% | +31.99% | +93.84% | +93.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 6 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+5.5% Q4'25: +13.0% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-1.1% Q4'25: -5.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+6.0% Q4'25: +8.3% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+5.4% ★ Q4'25: +5.6% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+7.6% ★ Q4'25: +16.4% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: -0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×3.13× Q4'25: 1.46× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.15B
est: 3.22B (-2.4%)
|
3.17B
est: 3.17B (0.0%)
|
3.31B
est: 3.29B (+0.5%)
|
3.48B
est: 3.46B (+0.6%)
|
3.83B
est: 3.84B (0.0%)
|
4.01B
est: 4.01B (+0.2%)
|
3.75B
est: 3.80B (-1.5%)
|
3.92B
est: 3.92B (0.0%)
|
4.14B
est: 4.14B (+0.0%)
|
4.32B
4.30B – 4.35B
+4.6% YoY
|
4.50B
4.36B – 4.56B
+4.0% YoY
|
4.64B
4.63B – 4.65B
+3.2% YoY
|
4.85B
4.76B – 4.90B
+4.6% YoY
|
5.09B
5.00B – 5.14B
+4.9% YoY
|
| EBITDA |
178.39M
est: 260.58M (-31.5%)
|
147.70M
est: 177.07M (-16.6%)
|
254.69M
est: 153.40M (+66.0%)
|
302.78M
est: 259.93M (+16.5%)
|
300.34M
est: 266.78M (+12.6%)
|
290.46M
est: 273.45M (+6.2%)
|
306.92M
est: 303.58M (+1.1%)
|
331.31M
est: 313.04M (+5.8%)
|
339.18M
est: 330.12M (+2.7%)
|
345.18M
343.32M – 347.62M
+4.6% YoY
|
358.93M
348.03M – 363.80M
+4.0% YoY
|
370.37M
369.39M – 371.35M
+3.2% YoY
|
387.32M
380.33M – 391.34M
+4.6% YoY
|
406.12M
398.78M – 410.33M
+4.9% YoY
|
| EBIT |
142.76M
est: 174.94M (-18.4%)
|
113.89M
est: 140.72M (-19.1%)
|
163.92M
est: 115.84M (+41.5%)
|
209.36M
est: 177.06M (+18.2%)
|
201.93M
est: 181.72M (+11.1%)
|
194.85M
est: 186.27M (+4.6%)
|
204.42M
est: 201.57M (+1.4%)
|
221.54M
est: 207.86M (+6.6%)
|
222.78M
est: 219.20M (+1.6%)
|
229.20M
227.96M – 230.82M
+4.6% YoY
|
238.33M
231.09M – 241.56M
+4.0% YoY
|
245.92M
245.27M – 246.58M
+3.2% YoY
|
257.18M
252.53M – 259.85M
+4.6% YoY
|
269.66M
264.79M – 272.46M
+4.9% YoY
|
| Net Income |
118.80M
est: 112.14M (+5.9%)
|
147.55M
est: 117.92M (+25.1%)
|
124.99M
est: 151.22M (-17.3%)
|
172.25M
est: 130.57M (+31.9%)
|
167.68M
est: 134.01M (+25.1%)
|
165.13M
est: 160.50M (+2.9%)
|
173.60M
est: 169.68M (+2.3%)
|
182.95M
est: 169.11M (+8.2%)
|
181.10M
est: 182.71M (-0.9%)
|
190.14M
185.67M – 194.62M
+4.1% YoY
|
212.09M
208.64M – 215.55M
+11.5% YoY
|
222.03M
216.92M – 228.97M
+4.7% YoY
|
239.28M
233.66M – 242.50M
+7.8% YoY
|
263.42M
257.23M – 266.97M
+10.1% YoY
|
| SGA |
54.85M
est: 68.45M (-19.9%)
|
59.83M
est: 548.95M (-89.1%)
|
61.80M
est: 619.47M (-90.0%)
|
64.27M
est: 578.77M (-88.9%)
|
74.79M
est: 594.02M (-87.4%)
|
82.15M
est: 608.87M (-86.5%)
|
99.55M
est: 102.69M (-3.1%)
|
82.91M
est: 105.90M (-21.7%)
|
195.72M
est: 111.67M (+75.3%)
|
116.77M
116.14M – 117.59M
+4.6% YoY
|
121.42M
117.73M – 123.07M
+4.0% YoY
|
125.29M
124.96M – 125.62M
+3.2% YoY
|
131.02M
128.66M – 132.38M
+4.6% YoY
|
137.38M
134.90M – 138.81M
+4.9% YoY
|
| EPS |
2.43
est: 2.25 (+8.1%)
|
3.00
est: 2.23 (+34.3%)
|
2.54
est: 2.73 (-7.0%)
|
3.48
est: 2.72 (+27.9%)
|
3.38
est: 3.36 (+0.7%)
|
3.32
est: 3.27 (+1.4%)
|
5.72
est: 3.40 (+68.1%)
|
3.67
est: 3.41 (+7.7%)
|
3.63
est: 3.74 (-2.9%)
|
3.80
3.72 – 3.90
+1.7% YoY
|
4.25
4.18 – 4.32
+11.8% YoY
|
4.49
4.35 – 4.59
+5.7% YoY
|
4.80
4.68 – 4.86
+6.8% YoY
|
5.28
5.16 – 5.35
+10.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares SMIM ETF (CH) CSSMIM.SW | 1.53% | 22.69M | 0.45% |
| 2 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.76% | 2.39M | 0.31% |
| 3 | iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE | 0.71% | 4.88M | 0.20% |
| 4 | iShares Swiss Dividend ETF (CH) CHDVD.SW | 0.60% | 58.68M | 0.15% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.41% | 1.40M | 0.23% |
| 6 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.41% | 1.40M | 0.23% |
| 7 | Alliance Bernstein - AB International Low Volatility Equity ETF ILOW | 0.40% | 7.23M | 0.50% |
| 8 | iShares MSCI Europe Small-Cap ETF IEUS | 0.35% | 612.1K | 0.41% |
| 9 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.35% | 11.79M | 0.30% |
| 10 | Fidelity International Multifactor ETF FDEV | 0.29% | 780.3K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marc Werner | Chief Executive Officer | 1M | male |
| Jörg Kneubühler | Advisor | 202.0K | — |
| Cécile Matter | Group General Counsel | — | female |
| Daniele Madonna | Chief of Pharmacies Category Management & Health Services | — | male |
| Iris Muller | Chief Communications Officer | — | female |
| Julian Fiessinger | Chief Financial Officer | — | male |
| Thomas F. Szuran | Deputy Chief Executive Officer of Galenica Group & Chief of Products & Home Care | — | — |
| Andreas Koch | Chief of Wholesale & Logistics | — | male |
| Virginie Pache Jeschka | Chief of Pharmacies Sales | — | female |
| Arianne Hasler | Chief People & Culture | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GALE.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
